Iteos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of Galaxies Lung-201 Study of Belrestotug + Dostarlimab in First-Line, Pd-L1 High Non-Small Cell Lung Cancer Patients
Iteos宣佈，在Belrestotug + Dostarlimab一線治療Pd-L1高非小細胞肺癌患者的Galaxies Lung-201研究的隨訪中期分析中，觀察到每個劑量都具有臨床意義的客觀緩解率。
